



PRESS RELEASE

Trillium Therapeutics Inc. announces Internationally Renowned Scientists to join New Scientific Advisory Board

Toronto, Canada – September 12th, 2003 - Trillium Therapeutics Inc. (TTI) today announced that it has formed a new Scientific Advisory Board (SAB), following the company's successful Series A financing. The new SAB has been assembled to guide and accelerate the advancement of TTI's therapeutic candidates into clinical testing. New members Drs. Mohammed Sayegh, Brian Barber and Vijay Kuchroo join SAB chairman, Dr. Gary Levy. "The composition of an SAB is vital to a company like ours", stated Dr. Bob Uger, TTI's Director, Research & Development. "The wide range of complimentary scientific and medical expertise of these four highly regarded scientists will ensure the continuance of TTI's world class Immunology research."

Dr. Levy is the Medical Director of the Multi-Organ Transplant Program at Toronto General Hospital, University Health Network and Professor of Medicine at the University of Toronto. He is also the Division Director of Gastroenterology for the Department of Medicine and Surgery.

Dr. Sayegh, the past President of the American Society of Transplantation and an Associate Professor of Medicine at Harvard Medical School, is the Research Director of the Laboratory of Immunogenetics and Transplantation at the Brigham and Women's Hospital. He is also Research Director of the Nephrology Division at Children's Hospital in Boston.

Dr. Barber, a former Professor in the Department of Immunology at the University of Toronto, is Chief Scientific Officer and Senior Vice President at Mojave Therapeutics, Hawthorne, NY. Prior to joining Mojave, he was Assistant Vice President of Immunology at Aventis Pasteur, Canada.

Dr. Kuchroo is an Associate Professor of Neurology at Harvard Medical School and Brigham and Women's Hospital. As a world-leading researcher in immunoregulation and autoimmunity, he serves on numerous national and international review and advisory boards.

September 15, 2003

Trillium Therapeutics Inc., a privately held Research and Development (R&D) company, specializes in the development of innovative therapies that restore balance to the immune system in conditions associated with aberrant and harmful immune responses, such as autoimmune and inflammatory disorders, graft rejection and viral hepatitis. The Company identifies therapeutic candidates with promising preclinical profiles and advances these into clinical testing, with the primary objective of demonstrating safety and efficacy in humans. The Company has two lead development candidates, a CD200 fusion protein (CD200Fc) and an Fgl2-specific monoclonal antibody (Fgl2 Mab). TTI has a variety of external R&D collaborations, including several with major pharmaceutical and biotechnology companies.

- 30 -

For further information, please contact:

Niclas Stiernholm, Ph.D.
Chief Executive Officer
Trillium Therapeutics Inc.
96 Skyway Avenue
Toronto, Ontario, M9W 4Y9
Canada

Tel: (416) 595-0627
Fax: (416) 595-5835
niclas@trilliumtherapeutics.com
www.trilliumtherapeutics.com